The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-27. Anything still debated is marked as such rather than presented as settled.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Oplophorus-luciferin 2-monooxygenase (EC 1.13.12.13), also known as Oplophorus luciferase (referred in this article as OpLuc) is a luciferase, an enzyme, from the deep-sea shrimp Oplophorus gracilirostris, belonging to a group of coelenterazine luciferases. Unlike other luciferases, it has a broader substrate specificity and can also bind to bisdeoxycoelenterazine efficiently. It was the third example of a luciferase (Other than Aequorea and Renilla) to be purified in lab. The systematic name of this enzyme class is Oplophorus-luciferin:oxygen 2-oxidoreductase (decarboxylating). This enzyme is also called Oplophorus luciferase.
=== Housing === In 2026, Pritzker proposed the "Building Up Illinois Developments" (BUILD) plan for approval by the Illinois General Assembly to amend the fiscal year 2027 state budget, which involves amending the Illinois Municipal Code to relax zoning restrictions, permit greater volume of single-family housing units on lots, legalize the construction accessory dwelling units—granny flats, backyard cottages and above-garage apartments—on residential properties, and prohibit the enactment of minimum parking requirements for certain types of residential and mixed-use housing typically set by municipal governments, in order to spur housing construction and development to reduce costs and meet the state's housing supply needs. The plan also prevents building codes from prohibiting the construction of single-stair residential suites. On February 19, 2026, Representative Kam Buckner introduced the plan in the Illinois House of Representatives as HB5626. Accordingly, Pritzker's administration also authorized the Illinois Housing Development Authority to provide down-payment assistance through the IDHAccess Home program, calculated at 6% of the purchase price up to $15,000, for qualified, low- to middle-income homebuyers who do not own a home or have not owned one in the preceding three years, as well as veterans.
==== Non-Hodgkin lymphoma ==== Results from several studies indicate that, compared to other autoimmune diseases, Sjögren's disease is associated with a notably high incidence of non-Hodgkin lymphoma, a cancer of white blood cells. About 5% of patients with Sjögren's develop some form of lymphoid malignancy. Patients with severe cases are much more likely to develop lymphomas than patients with mild or moderate cases. The most common lymphomas are salivary extranodal marginal zone B cell lymphomas (MALT lymphomas in the salivary glands) and diffuse large B-cell lymphoma. Lymphomagenesis in primary Sjögren's disease patients is considered a multistep process, with the first step being chronic stimulation of autoimmune B cells, especially B-cells that produce rheumatoid factor at sites targeted by the disease. This increases the frequency of oncogenic mutation, leading to any dysfunction at checkpoints of autoimmune B-cell activation to transform into malignancy. A study's findings concluded that continuous stimulation of autoimmune B cells leads to subtle germinal abnormalities in genes having specific consequences in B cells, which underlie the susceptibility to lymphoma.
IgA vasculitis (Henoch-Schönlein purpura) Acute hemorrhagic edema of infancy Urticarial vasculitis Cryoglobulinemic vasculitis Erythema elevatum diutinum Granuloma faciale ANCA-associated vasculitis Arthropod bites Platelet dysfunction or deficiency Cholesterol emboli Septic emboli Livedoid vasculopathy
Sources: en.wikipedia.org
Crucibles used to contain plutonium need to be able to withstand its strongly reducing properties. Refractory metals such as tantalum and tungsten along with the more stable oxides, borides, carbides, nitrides and silicides can tolerate this. Melting in an electric arc furnace can be used to produce small ingots of the metal without the need for a crucible. Cerium is used as a chemical simulant of plutonium for development of containment, extraction, and other technologies.
Masculinizing hormone therapy – for transgender men or transmasculine people; consists of androgens and occasionally antiestrogens. Feminizing hormone therapy – for transgender women or transfeminine people; consists of estrogens with or without antiandrogens. Eligibility for GAHT may require an assessment for gender dysphoria or persistent gender incongruence; many medical institutions now use an informed consent model, which ensures patients are informed of the procedure process, including possible benefits and risks, while removing many of the historical barriers needed to start hormone therapy. Treatment guidelines for therapy have been developed by several medical associations. However, many transgender people of all ages safely obtain and administer hormone therapy to themselves (DIY transgender hormone therapy) without recourse to institutional 'gatekeepers'. This helps them to overcome legal barriers to care, and to obtain higher, more effective dosages and a wide range of medications. Non-binary people may also engage in hormone therapy in order to achieve a desired balance of sex hormones or to help align their bodies with their gender identities. Many transgender people obtain hormone replacement therapy from a licensed health care provider, while others obtain and self-administer hormones.
NOS Journaal – one of the most important news programmes in the Netherlands, broadcast on all public stations whenever possible. The flagship edition is the 8 pm bulletin on NPO 1, often called achtuurjournaal, supplemented by two shorter editions at 6pm & midnight and hourly bulletins throughout the day. NOS Jeugdjournaal – A news programme aimed at 8–12-year-olds, aired on children's channel NPO Zapp. It is broadcast at 7pm and lasts 20 minutes, and a short bulletin is broadcast every weekday at 8:45 am when primary school starts. NOS Studio Sport – A sports programme covering the most popular sports. It has the right to broadcast major sports tournaments, like the Olympic Games and the FIFA World Cup and UEFA Euro. The NOS no longer has the right to broadcast full matches of the Eredivisie, but Studio Sport Eredivisie still provides summaries of matches played. The programme also covers matches and competitions in other sports, most notably tennis, ice skating, cycling, and field hockey. The editorial staff is also responsible for the NOS Sportjournaal, a news programme about sport, and NOS Studio Voetbal, a football talkshow on Sunday evening about the Eredivisie, the Netherlands national team and other news in football. NOS Journaal op 3 – a 60-second news bulletin aimed at teenagers and young adults, aired on NPO 3, since 2011 called NOS op 3. NOS Den Haag Vandaag – a daily roundup of events from parliamentary sessions and political reports, produced in cooperation with the NOS, NTR and BNNVARA.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.